



### Adcirca<sup>®</sup> (tadalafil) – First-time generic

- On August 10, 2018, [Mylan launched](#) an [AB-rated](#) generic version of Eli Lilly's [Adcirca \(tadalafil\)](#) tablets.
  - Mylan was granted 180-days exclusivity.
- Adcirca is approved to treat pulmonary arterial hypertension (WHO Group 1) to improve exercise ability.
- Tadalafil is also available as the brand product [Cialis<sup>®</sup>](#), which is approved for the treatment of erectile dysfunction (ED), the signs and symptoms of benign prostatic hyperplasia (BPH), and ED/BPH.
- According to IQVIA, U.S. sales for tadalafil 20 mg tablets were approximately \$510 million for the 12 months ending on May 31, 2018.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.